| In a bid to shorten the time-to-market for new | | | | multiple sites, teams and trials, hence, resources are |
| drugs, pharmaceutical companies utilize developments | | | | better utilized |
| in information technology efficiently to get better and | | | | - Improves productivity: Lost records can be easily |
| faster results. CTMS is one such web-based system | | | | retrieved, overdue tasks and incomplete records can |
| that helps manage clinical trials effectively and help | | | | be monitored electronically. So, this way productivity |
| hasten the drug development cycle. Also, just like | | | | is tracked and hence can be greatly improved |
| any other pharmacovigilance system, CTMS also | | | | - Reduces costs: Effectively reduces the cost of |
| helps improve the quality of drugs and protect public | | | | managing huge volumes of data, as data storage is |
| health. | | | | electronically processed. |
| Here are the key benefits of a web-based CTMS: | | | | - Improves quality of CT: Helps better evaluation of |
| - Streamlines the CT process: CTMS consolidates | | | | adverse reactions, minimizes data entry errors and |
| monitoring and management of all activities pertaining | | | | improves tracking of drug safety issues |
| to clinical trials so all the data are easily accessible | | | | Faster access for regulatory authorities: The prime |
| - Anytime, anywhere access: Web-based CTMS can | | | | aim of any pharmacovigilance system is to improve |
| be accessed anytime, anywhere, even several | | | | drug safety and to meet up with the stringent drug |
| thousand geographical miles away from the clinical | | | | regulations. A CTMS helps smoothen the regulatory |
| trials destination. This allows for faster transfer of | | | | assessment and reporting process, thereby |
| data and easier co-relative studies. | | | | shortening the time taken to develop and market a |
| - Better utilization of resources: As workflow process | | | | new drug. |
| is smooth due to instant availability of data across | | | | |